Amaza™ 4D-Nucleofector™ Protocol for Primary Mammalian Neurons
For 4D-Nucleofector™ X Unit—Transfection in suspension

Primary mammalian neurons, primary neurons freshly isolated embryonic (E18) or neonatal (P1–2) mammalian neural tissues.

Note
Mammalian neurons display significant phenotypic variations due to the wide range of both species and tissues from which they may be sourced. This basic protocol describes how to easily define optimal Nucleofection™ Conditions for different mammalian neural cells. We recommend to first test a set of pre-selected Nucleofector™ Programs together with the P3 Primary Cell 4D-Nucleofector™ X Kit.

Product Description

Recommended Kit[s]–P3 Primary Cell 4D-Nucleofector™ X Kit

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>V4XP-3012</th>
<th>V4XP-3024</th>
<th>V4XP-3032</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfection volume</td>
<td>100 µl</td>
<td>100 µl</td>
<td>20 µl</td>
</tr>
<tr>
<td>Size [reaction]</td>
<td>2 x 6</td>
<td>24</td>
<td>2 x 16</td>
</tr>
<tr>
<td>Nucleofector™ Solution</td>
<td>2 x 0.675 ml (0.492 ml + 27 % overfill)</td>
<td>2.25 ml (1.968 ml + 13 % overfill)</td>
<td>0.675 ml (0.525 ml + 22 % overfill)</td>
</tr>
<tr>
<td>Supplement</td>
<td>2 x 0.15 ml (0.108 ml + 27 % overfill)</td>
<td>0.5 ml (0.432 ml + 13 % overfill)</td>
<td>0.15 ml (0.115 ml + 22 % overfill)</td>
</tr>
<tr>
<td>pmaxGFP™ Vector (1 µg/µl in 10 mM Tris pH 8.0)</td>
<td>50 µg</td>
<td>50 µg</td>
<td>50 µg</td>
</tr>
<tr>
<td>Single Nucleocuvette™ (100 µl)</td>
<td>12</td>
<td>24</td>
<td>-</td>
</tr>
<tr>
<td>16-well Nucleocuvette™ Strips (20 µl)</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
</tbody>
</table>

Storage and stability
Store Nucleofector™ Solution, Supplement and pmaxGFP™ Vector at 4 °C. For long-term storage, pmaxGFP™ Vector is ideally stored at -20 °C. The expiration date is printed on the solution box. Once the Nucleofector™ Supplement is added to the Nucleofector™ Solution, it is stable for three months at 4 °C.

Note
4D-Nucleofector™ Solutions could be only used with Nucleovettes™ (conductive polymer cuvettes), i.e. in the 4D-Nucleofector™ System and the 96-well Shuttle™ Device. They are not compatible with the Nucleofector™ II/2b Device.
### Optimization Guidelines

The initial optimization experiment is comprised of 16 reactions, using 7 different Nucleofector™ Programs plus 1 control tested in duplicate. The program which turns out to be the most appropriate Nucleofection™ Condition should be used for all subsequent transfections. A further fine tuning of the Nucleofection™ Condition can be performed with the help of our Scientific Support Team.

<table>
<thead>
<tr>
<th>Nucleocuvette™ Strip 1: P3 Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>A CA-138</td>
</tr>
<tr>
<td>B CL-133</td>
</tr>
<tr>
<td>C CU-110</td>
</tr>
<tr>
<td>D DC-100</td>
</tr>
<tr>
<td>E DC-104</td>
</tr>
<tr>
<td>F DR-114</td>
</tr>
<tr>
<td>G EM-110</td>
</tr>
<tr>
<td>H Negative control (no program)</td>
</tr>
</tbody>
</table>

### Required Material

**Note**

Please make sure that the entire supplement is added to the Nucleofector™ Solution. The ratio of Nucleofector™ Solution to supplement is 4.5 : 1 (see table 1)

- **4D-Nucleofector™ System** [4D-Nucleofector™ Core Unit and 4D-Nucleofector™ X Unit]
- Supplemented 4D-Nucleofector™ Solution at room temperature
- Supplied 100 µl single Nucleocuvette™or 20 µl 16-well Nucleocuvette™ Strips
- Supplied pmaxGFP™ Vector, stock solution 1µg/µl

**Note**

For positive control using pmaxGFP™, dilute the stock solution to an appropriate working concentration. Further details are provided in table 3 of this Optimized Protocol. The volume of substrate solution added to each sample should not exceed 10% of the total reaction volume (2 µl for 20 µl reactions; 10 µl for 100 µl reactions).

- Substrate of interest, highly purified, preferably by using endotoxin-free kits; A260 : A280 ratio should be at least 1.8
- Cell culture plates of your choice
- Poly-L-lysine (PLL) and laminin coated glass coverslips [Marienfeld; 15 mm] or PLL coated culture plates
- **Solution for coating**: 1 mg/ml poly-L-lysine (PLL; Sigma) dissolved in borate buffer, sterilized by filtration (as an alternative to PLL, poly-D-lysine can be used as well for cultivation over more than 3 days; 10 µg/ml laminin solution [Invitrogen, Cat. No. 23017-015]; PBS
- **Dissection solution**: 500 ml HBSS [Lonza; Cat. No. 10-508F], 5 ml penicillin/streptomycin [Lonza; Cat. No. 17-602E], 5 ml 1 M MgCl2, 3.5 ml 1 M Hepes (pH 7.3) and 5 ml 200 mM L-glutamine; sterilized by filtration and pre-cooled on ice before use
- **For detaching cells**: 1 mg/ml trypsin [Sigma; Cat. No. T4799] in calcium and magnesium-free HBSS [Lonza; Cat. No. 10-543F] or Trypsin/EDTA mixture [Lonza; Cat. No. 17-160; used as 1x solution]; HBSS [Lonza; Cat. No. 10-508F] for washing
- Culture medium [for embryonic neurons]: PNGM™ BulletKit™ [Lonza; Cat. No. CC-4461] including PNBM™ Basal Medium and PNGM™ SingleQuots™ Supplements (GA-1000, final concentration 0.1 %; NSF-1, final concentration 2 %; L-glutamine, final concentration 2 mM). The medium is supposed to be serum free. On occasion 5 % horse serum or FCS serum can be used transiently during plating of the cells
- Culture medium [for adult neurons]: PNBM™-A BulletKit™ [Lonza; Cat. No. CC-4512; for adult neurons] including PNBM™ Basal Medium and PNGM™-A SingleQuots™ Supplements (GA-1000, final concentration 0.1 %; NSF-1, final concentration 2 %; L-glutamine, final concentration 2 mM; additional components are included in the PNGM™-A SingleQuots™ Kit to adjust for unique growth conditions required for optimal growth and survival of adult neurons). The medium is supposed to be serum free. On occasion 5 % horse serum or FCS serum can be used transiently during plating of the cells. Optionally 5 µM Ara C [EMD Calbiochem; Cat. No. 251010] may be used 24 hours after plating to inhibit the proliferation of glial cells, which are more abundant in preparations from postnatal brains
- Recovery medium [optional]: In case of high mortality you may use a low calcium medium, e.g. RPMI [Lonza; Cat. No. 12-167F], for the transfer from the cuvette into the culture plate [see Note after 2.19]
- Prewarm appropriate volume of culture medium to 37 °C (see table 2)
- Appropriate number of cells/sample (see table 2)

### 1. Pre Nucleofection™

**Note**

This protocol only gives an outline for the isolation and culture of primary mammalian neurons. Please refer to more detailed protocols in the literature before starting the experiments. A selection of references is given at the end of this document.
Coating of culture plates
1.1 Add sufficient volume of poly-L-lysine solution to each well to cover the bottom surface
1.2 Incubate in a humidified 37 °C/5 % CO₂ incubator overnight
1.3 Wash 2 x with sterile water and dry
1.4 Fill each dish with culture medium and return to the incubator for at least 12 hours and up to 2 weeks

Preparation of coverslips (optional)
1.5 Place tissue culture treated coverslips into an appropriate culture dish [e.g., one slide per well of 12-well plate]
1.6 Add 400 μl poly-L-lysine solution and incubate in a humidified 37 °C/5 % CO₂ incubator overnight
1.7 Wash 2 x with sterile water and dry
1.8 Incubate coverslips in 400 μl laminin solution in a humidified 37 °C/5 % CO₂ incubator overnight
1.9 Wash 2 x with sterile PBS. For more details please refer to Zeitelhofer M et al. 2007 (see reference list at the end of this document)

Preparation of dissociated hippocampal or cortical neurons for Nucleofection™
1.10 Separate heads from rat embryos (E17-18) or early postnatal rats (P0-2)
1.11 Dissect brains from the skull and transfer them into a Petri dish with pre-cooled dissection solution
1.12 Cut brains along midline and extract hippocampi or cortices
1.13 Store hippocampi or cortices in at least 10 ml dissection solution in Falcon tubes on ice
1.14 Centrifuge at 80xg for 5 minutes and carefully remove supernatant [alternatively, if experienced, remove dissection solution by very careful decanting]
1.15 Add 1.5 ml trypsin solution and incubate for 10–20 minutes at 37 °C
1.16 After trypsinization, centrifuge at 80xg for 5 minutes and carefully remove supernatant [alternatively, if experienced, remove dissection solution by very careful decanting]
1.17 Wash two times with HBSS
1.18 After the second wash, add 1.5 ml of culture medium, prewarmed to 37 °C
1.19 Triturate about 20–30 x with a fire-polished Pasteur pipette until all pieces of tissue are homogenously dispersed
1.20 Triturate a second time for exactly 1 minute with a fire-polished Pasteur pipette
1.21 Add 5 ml of culture medium and count cells
1.22 Continue at step 2.1 of the Nucleofection™ Protocol

2. Nucleofection™
For Nucleofection™ Sample contents and recommended Nucleofector™ Program, please refer to Table 3.

2.1 Please make sure that the entire supplement is added to the Nucleofector™ Solution
2.2 Start 4D-Nucleofector™ System and create or upload experimental parameter file [for details see device manual]
2.3 Select/Check for the appropriate Nucleofector™ Program [see table 3]
2.4 Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media [see table 4] and pre-incubate/equilibrate plates in a humidified 37 °C/5 % CO₂ incubator
2.5 Pre-warm an aliquot of culture medium to 37 °C [see table 4]
2.6 Prepare plasmid DNA or pmaxGFP™ Vector or siRNA [see table 3]
2.7 Count an aliquot of the cells and determine cell density
2.8 Centrifuge the required number of cells [see table 3] at 80xg for 10 minutes at room temperature. Remove supernatant completely
2.9 Resuspend the cell pellet carefully in room temperature 4D-Nucleofector™ Solution [see table 3]
2.10 Prepare mastermixes by dividing cell suspension according to number of substrates
2.11 Add required amount of substrates to each aliquot [max. 10 % of final sample volume]
2.12 Transfer mastermixes into the Nucleocuvette™ Vessels

Note
As leaving cells in Nucleofector™ Solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

2.13 Gently tap the Nucleocuvette™ Vessels to make sure the sample covers the bottom of the cuvette
2.14 Place Nucleocuvette™ Vessel with closed lid into the retainer of the 4D-Nucleofector™ X Unit. Check for proper orientation of the Nucleocuvette™ Vessel
2.15 Start Nucleofection™ Process by pressing the “Start” on the display of the 4D-Nucleofector™ Core Unit [for details, please refer to the device manual]
2.16 After run completion, carefully remove the Nucleocuvette™ Vessel from the retainer
2.17 Incubate Nucleocuvette™ 10 minutes at room temperature
2.18 Resuspend cells with pre-warmed medium [for recommended volumes see table 5]. Mix cells by gently pipetting up and down two to three times. When working with the 100 μl Nucleocuvette™ use the supplied pipettes and avoid repeated aspiration of the sample
2.19 Plate desired amount of cells in culture system of your choice [for recommended volumes see table 5]
BioResearch
Amaxa™ 4D-Nucleofector™ Protocol
for Primary Mammalian Neurons

Note
As transfected neural cells can quickly form aggregates it is important to transfer cells to culture plate as quickly as possible after addition of medium.

Optional:
- If very high mortality is observed, a recovery step can be useful: immediately after Nucleofection™, add 100–300 μl pre-equilibrated recovery medium to the cuvette (instead of the standard culture media) and gently transfer it to a reaction tube
- Place the cell suspension in incubator for 5–10 minutes (="Recovery Step")
- Transfer the sample into the prepared culture dish with the coated coverslip and continue at 3.1 of the protocol

3. Post Nucleofection™
3.1 Incubate the cells in humidified 37 °C/5 % CO₂ incubator until analysis
3.2 Optionally (in case of much debris): Carefully replace half of the medium with fresh culture medium after 2–4 hours
3.3 Optionally (in case of much debris): Carefully replace the medium completely with fresh culture medium after 24 hours
3.4 After 24–48 hours of incubation viability of cells can be evaluated by proportion of cells attached to the cover slips. Depending on the gene, expression is often detectable after 6–8 hours and can be observed up to 12–14 days after Nucleofection™
3.5 Replace half of the culture medium with fresh medium once a week

Additional Information
For an up-to-date list of all Nucleofector™ References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA /Canada
Phone: 800 521 0390 (toll-free)
Fax: 301 845 8338
E-mail: scientific.support@lonza.com

Europe and Rest of World
Phone: +49 221 99199 400
Fax: +49 221 99199 499
E-mail: scientific.support.eu@lonza.com

References

Lonza Cologne GmbH
50829 Cologne, Germany

Please note that the Amaxa™ Nucleofector™ Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector™ Technology, comprising Nucleofection™ Process, Nucleofector™ Device, Nucleofector™ Solutions, Nucleofector™ 96-well Shuttle System and 96-well Nucleocuvette™ plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH.

Amaxa, Nucleofector, Nucleofection, 4D-Nucleofector, 96-well Shuttle, Nucleocuvette, maxGFP, PNBM, PNGM, SingleQuot and BulletKit are either registered trademarks or trademarks of the Lonza Group or its affiliates.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepodfluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2010, Lonza Cologne GmbH. All rights reserved.
### Table 1: Volumes required for a single reaction

<table>
<thead>
<tr>
<th></th>
<th>100 µl Single Nucleocuvette*</th>
<th>20 µl Nucleocuvette* Strip</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume of Nucleofector™ Solution</td>
<td>82 µl</td>
<td>16.4 µl</td>
</tr>
<tr>
<td>Volume of Supplement</td>
<td>18 µl</td>
<td>3.6 µl</td>
</tr>
</tbody>
</table>

### Table 2: Required amounts of cells and media for Nucleofection™

<table>
<thead>
<tr>
<th></th>
<th>100 µl Single Nucleocuvette*</th>
<th>20 µl Nucleocuvette* Strip</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture medium per sample post Nucleofection™ (for transfer and culture)</td>
<td>0.8 ml</td>
<td>240 µl</td>
</tr>
<tr>
<td>Cell number per Nucleofection™ Sample</td>
<td>4–5 x 10⁶ (Lower or higher cell numbers may influence transfection results)</td>
<td>2.5 x 10⁵ (Lower or higher cell numbers may influence transfection results)</td>
</tr>
</tbody>
</table>

### Table 3: Contents of one Nucleofection™ Sample and recommended program

<table>
<thead>
<tr>
<th></th>
<th>100 µl Single Nucleocuvette*</th>
<th>20 µl Nucleocuvette* Strip</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cells</td>
<td>4–5 x 10⁶</td>
<td>2.5 x 10⁵</td>
</tr>
<tr>
<td>Substrate*</td>
<td>pmaxGFP™ Vector</td>
<td></td>
</tr>
<tr>
<td>or</td>
<td>2 µg</td>
<td>0.4 µg</td>
</tr>
<tr>
<td>or</td>
<td>plasmid DNA (in H₂O or TE)</td>
<td></td>
</tr>
<tr>
<td>or</td>
<td>1–3 µg</td>
<td>0.1–0.6 µg</td>
</tr>
<tr>
<td>or</td>
<td>siRNA</td>
<td></td>
</tr>
<tr>
<td>or</td>
<td>30–300nm siRNA</td>
<td></td>
</tr>
<tr>
<td>or</td>
<td>(3–30 pmol/sample)</td>
<td></td>
</tr>
<tr>
<td>or</td>
<td>30–300nm siRNA</td>
<td></td>
</tr>
<tr>
<td>or</td>
<td>(0.6–6 pmol/sample)</td>
<td></td>
</tr>
<tr>
<td>P3 4D-Nucleofector™ X Solution</td>
<td>100 µl</td>
<td>20 µl</td>
</tr>
<tr>
<td>Program</td>
<td>CA-138 or</td>
<td>CA-138 or</td>
</tr>
<tr>
<td>or</td>
<td>CL-133 or</td>
<td>Cl-133 or</td>
</tr>
<tr>
<td>or</td>
<td>CU-110 or</td>
<td>CU-110 or</td>
</tr>
<tr>
<td>or</td>
<td>DC-100 or</td>
<td>DC-100 or</td>
</tr>
<tr>
<td>or</td>
<td>DR-104 or</td>
<td>DR-104 or</td>
</tr>
<tr>
<td>or</td>
<td>DR-114 or</td>
<td>DR-114 or</td>
</tr>
<tr>
<td>or</td>
<td>EM-110</td>
<td>EM-110</td>
</tr>
</tbody>
</table>

* Volume of substrate should comprise maximum 10% of total reaction volume.

### Table 4: Culture volumes required for post Nucleofection™ Steps

<table>
<thead>
<tr>
<th></th>
<th>100 µl Single Nucleocuvette*</th>
<th>20 µl Nucleocuvette* Strip*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coated 6-well culture plate</td>
<td>300 µl</td>
<td>-</td>
</tr>
<tr>
<td>Coated 96-well culture plate</td>
<td>-</td>
<td>160 µl</td>
</tr>
<tr>
<td>Culture medium to be added to the sample post Nucleofection™</td>
<td>500 µl</td>
<td>80 µl</td>
</tr>
</tbody>
</table>

* Maximum cuvette volume 200 µl

### Table 5: Recommended volumes for sample transfer into culture plate

<table>
<thead>
<tr>
<th></th>
<th>100 µl Single Nucleocuvette*</th>
<th>20 µl Nucleocuvette* Strip*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture medium to be added to the sample post Nucleofection™</td>
<td>500 µl</td>
<td>80 µl</td>
</tr>
<tr>
<td>Volume of sample transferred to culture plate</td>
<td>complete sample [use supplied pipettes]</td>
<td>40 µl</td>
</tr>
</tbody>
</table>

* Maximum cuvette volume 200 µl